Top Tweets for #IMMotion010
A patient-centered toxicity framework and quality of life in adjuvant #RCC. Elizabeth Nally @QMBCI sits down with @ERPlimackMD @FoxChaseCancer shares a patient-derived toxicity framework developed from interviews with #KidneyCancer patients and applied to #IMmotion010, a global phase 3 adjuvant trial. #WatchNow > https://t.co/8qsbQRnWYo
So much to learn from "negative" trials - a trove of data has poured out from the adjuvant #IMmotion010 study (#atezolizumab v pbo in #localized #kidneycancer), including the #KIM1 story first presented by @AlbigesL & published by @brian_rini in @Annals_Oncology. Now - in @EUplatinum - @VincentWenxinXu describes the evolution of tissue genomics from primary tumor, providing unique perspectives of mechanisms of resistance that are only possible in the context of large, randomized datasets.
See below for our tweetorial from last year's @ASCO meeting or follow this link for the paper: https://t.co/XlgB5AlRAN
With all the amazing presentations at #ASCO25, just wanted to take a moment to share some of our data related to #biomarkers from the #IMmotion010 phase III study, a trial of adjuvant #atezolizumab vs pbo. A tremendous team helped me put this together, including @VincentWenxinXu @AlbigesL @brian_rini & the tremendous team at @Roche @genentech who saw the value in the extensive correlatives! We looked at ... (1/9)
With all the amazing presentations at #ASCO25, just wanted to take a moment to share some of our data related to #biomarkers from the #IMmotion010 phase III study, a trial of adjuvant #atezolizumab vs pbo. A tremendous team helped me put this together, including @VincentWenxinXu @AlbigesL @brian_rini & the tremendous team at @Roche @genentech who saw the value in the extensive correlatives! We looked at ... (1/9)
Congrats to #DrJoseKaram @MDAndersonNews & @virajmaster @WinshipAtEmory who drove this important subanalysis of pts in #IMmotion010 who had sarcomatoid features. No statistically significant difference in DFS - curves shown below. So appreciative of @UroOnc members like Jose & Viraj who really drove accrual to this trial. @Robert_Uzzo @wandering_gu @KidneyCancerDoc
Watch an analysis of top abstracts from #ASCO24 in #GU #Cancer with experts Dr. Christian Kollmannsberger, @LuciaNappi4 and @navstruck.
https://t.co/JszHahIlp8
#CHAARTED2 #TheMAST #EMBARK #CYCLONE2 #PSMAfore #CLEAR #KEYNOTE426 #IMmotion010 #GUCancer #MedOnc
Looking forward to joining @UrogerliMD & @VikramNarayan for a quick #ASCO24 update for @UroOnc! Still time to register ... I will be discussing the stellar @ASCO oral presentation given by @AlbigesL related to #KIM1 in #IMmotion010!
https://t.co/YR8NqFbOtb
Glad you captured this moment @LauraBukavinaMD. Had the pleasure of co-chairing #Immotion010 w @Robert_Uzzo, an #SUOCTC trial. He was thoughtful & insightful through the process, but moreover, inspired our colleagues (@virajmaster, #JoseKaram et al) to join forces & finish this study quickly. Have been to many mentorship talks - this one was different. If you're not at #SUO23, see if you can access virtually!
A well-deserved standing ovation for @Robert_Uzzo of @FoxChaseCancer, recipient of the Joseph Smith Mentorship Award. A true giant in the field .. colleague, teacher, mentor and sponsor for many, our field is fortunate to have individuals like him. #SUO23
Atezolizumab as adjuvant therapy after resection for patients with #RCC with increased risk of recurrence: #IMmotion010 trial. @WallisCJD @UofT & @zklaassen_md @GACancerCenter discuss in this UroToday #JournalClub > https://t.co/P57XSrucDU @TheLancet
Atezolizumab as adjuvant therapy after resection for patients with #RCC with increased risk of recurrence: #IMmotion010 trial. @WallisCJD @UofT & @zklaassen_md @GACancerCenter discuss in this UroToday #JournalClub > https://t.co/P57XSrucDU @TheLancet
Some thoughts on discrepancies between adjuvant RCC trials. #RCC #Immotion010 #Keynote564 @d_borchiellini @ZineEddineKhene
https://t.co/ak1fgO0dKd
8/ Data from the #IMmotion010 trial: adjuvant atezolizumab unfortunately did not meet its primary endpoint of improved DFS in #RCC at high risk of recurrence after nephrectomy.
@montypal @UzzoRob #AxelBex @AlbigesL @brian_rini @crisuarez08
https://t.co/Q2Mx9bQnZo
Always a pleasure to record w @montypal as we re-hashed #ESMO22 — #PROSPER #IMMotion010 #Checkmate914 #COSMIC313 #EV103cohortK — give a listen @CancerDotNet!
https://t.co/V1116Fn8jc
📣 NEW PODCAST! @ILSONDavid @montypal and @TiansterZhang discuss #NewResearch from #ESMO22 in gastrointestinal and genitourinary cancers https://t.co/0WnMOcXJBz #CancerResearch #LiverCancer #ColorectalCancer #StomachCancer #KidneyCancer #BladderCancer and #ProstateCancer #CRCSM
🧵#UromigosLive #KidneyCancer Poll 1: You've seen the data for adjuvant therapy at #ESMO22 from #CM914, #IMmotion010 & #PROSPER, summarized against #KN564 below. No @myESMO data was +, but updated data from #KN564 in @TheLancetOncol continues to hold. ‼️POLLS TO FOLLOW‼️ (1/6)
The #OncoAlertTopTweet 🚨 #ESMO22 Day 3⃣
Tweet @OncoAlert
The Daily Wrap Up of Day 2⃣
#Bellini
#ImMotion010
@montypal @ErikaHamilton9 @matteolambe @neerajaiims @VivekSubbiah @DrChoueiri
Best, @weoncologists
The #OncoAlertTopTweet 🚨 Day 2⃣ #ESMO22
Tweet @montypal 🇺🇸
Deepest Congratulations to our @OncoAlert colleague on this wonderful publication
#adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex
#RCC #KidneyCancer
@TheLancet
Best,
@weoncologists
Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) https://t.co/F5Y5HyNaxY
It was an honor to have had the opportunity to work with this magnificent team!
@TheLancet #IMmotion010 #ESMO22
Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) https://t.co/F5Y5HyNaxY
#IMmotion010: Efficacy and safety from the phase III study of atezolizumab vs PBO as adjuvant therapy in patients with #RCC at increased risk of recurrence after resection - Axel Bex, MD, PhD @RoyalFreeNHS. #ESMO22 written coverage > https://t.co/BVyy51cjVZ @zklaassen_md @myESMO
4. #IMMotion010: Ph 3, Adj Rx in high risk RCC post nephrectomy, atezolizumab vs placebo by @montypal @tompowles1
- No improved clinical outcomes
- mDFS 57·2 mos vs. 49·5 mos
- Awaiting OS Data for Adj pembro #KN564. Referring back to JLarkin: "use IO now or later"?
5/5
Day 2 #ESMO22 Highlights #CommunityOncology
1. #LEAP002 - HCC shared by @GillSharlene
2. #RATIONALE301 - HCC shared by @ArndtVogel
3. #ADAPTET - adj breast CA shared by @ErikaHamilton9
4. #IMMotion010 - adj RCC by @montypal
@myESMO #MedTwitter #GUSM #GISM #bcsm
1/5
Our study, #Immotion010, utilized a very similar design. Lots of similarities in pt characteristics, but will point out that our study was (1) smaller and (2) included a different M1 population (refer to paper for details) (4/10)
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89.1M followers
Taylor Swift
@taylorswift13
83M followers
Lady Gaga
@ladygaga
74.5M followers
Virat Kohli
@imvkohli
72M followers
Kim Kardashian
@kimkardashian
70.5M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.9M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.1M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers